ABIVAX successfully completes first-in-man study of ABX464, a highly differentiated small molecule targeting HIV
03-Dec-2014 -
ABIVAX announced the successful completion of its Phase 1 first-in-man study of ABX464, which has been designed to potentially deliver a number of important clinical benefits when treating patients with HIV.
AXB464 is a small molecule with the potential to inhibit HIV replication. Through its ...
HIV
phase I studies